In this issue:
Persistence and remission with guselkumab vs IL-17 inhibitors
Dupilumab up to 1 year in children with atopic dermatitis
Erenumab for persistent erythema and flushing in rosacea
Guselkumab for pityriasis rubra pilaris
Patient-reported outcomes for psoriasis treated with biologics
Vaccination rates among patients on biologics
Vaccination recommendations for biologics and oral treatments
Inflammatory cytokines during omalizumab in chronic spontaneous urticaria
Biologics and all-cause mortality in patients with psoriasis
Secukinumab for moderate-to-severe hidradenitis suppurativa
Expert contributor
Dr Annika Smith is a Fellow of the Australasian College of Dermatologists and Consultant Dermatologist in public and private settings in Sydney. Annika undertook training at the prestigious St John’s Institute of Dermatology London, followed by further sub-specialty training in New York. Annika has a special interest in complex medical dermatology, including clinical and research […]
Stay up to date with our latest clinical information.
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.